Mae’n bwysig fy mod yn ailadrodd bod y Cyd-bwyllgor wedi cynghori y dylid cynnig brechlyn i fenywod beichiog yr un pryd â menywod nad ydynt yn feichiog, ar sail eu grŵp oedran a’u grŵp risg glinigol. Erbyn hyn, mae tystiolaeth helaeth ar gael o’r defnydd o’r brechlynnau Pfizer a Moderna yn yr Unol Daleithiau ar ôl eu rhyddhau ar y farchnad, heb unrhyw signalau diogelwch hyd yma. Felly, y brechlynnau hyn yw’r rhai a ffefrir ar gyfer menywod beichiog. Dylai clinigwyr drafod risgiau a manteision brechu â’r fenyw, a dylid dweud wrthi am y dystiolaeth gyfyngedig, ond sy’n dod i’r amlwg, ynghylch diogelwch brechu yn ystod beichiogrwydd. Nid oes angen ichi wneud y penderfyniad ar eich pen eich hun, a byddem yn eich annog i’w drafod â’ch meddyg neu’ch bydwraig. Y cyngor i fenywod beichiog sydd wedi dechrau cael eu brechu gyda’r brechlyn AstraZeneca yw parhau â’u cwrs brechu gyda’r un brechlyn.
It is important that I reiterate that the JCVI have advised that women who are pregnant should be offered vaccination at the same time as non-pregnant women, based on their age and clinical risk group. There is now extensive post-marketing experience of the use of the Pfizer and Moderna vaccines in the USA with no safety signals so far. These vaccines are therefore the preferred vaccines to offer to pregnant women. Clinicians should discuss the risks and benefits of vaccination with the woman, who should be told about the limited but emerging evidence regarding safety for vaccination in pregnancy. You don’t have to make the decision alone, and we would encourage you talk it through with your doctor or midwife. Pregnant women who commenced vaccination with AstraZeneca, are advised to complete their vaccination course with the same vaccine.